A group of potassium-channel blockers-acetylcholine releasers: new potentials for Alzheimer disease? A review.
This review of the literature examines systematically the data currently available for potassium-channel blockers to reassess their clinical potential in Alzheimer disease. The conclusion is that potassium-channel blockers may have been dismissed prematurely for the treatment of Alzheimer disease, an impression supported by data indicating intimate relationships between potassium-channel blockade and cholinergic transmission.
Lavretsky
E P
EP
West Los Angeles VA Medical Center, California.
Jarvik
L F
LF
D000109:Acetylcholine / Q000378:metabolism*; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D001921:Brain / Q000187:drug effects* / Q000503:physiopathology; D002491:Central Nervous System Agents / Q000627:therapeutic use*; D006801:Humans; D015221:Potassium Channels / Q000187:drug effects* / Q000502:physiology; D011950:Receptors, Cholinergic / Q000187:drug effects / Q000502:physiology; D013329:Structure-Activity Relationship
D002491:Central Nervous System Agents; D015221:Potassium Channels; D011950:Receptors, Cholinergic; D000109:Acetylcholine